Us General Management, Strategy Pluvicto® Radioligand Therapy (Rlt) Prostate Cancer
CurrentUS General Management, Strategy and operational leader for PLUVICTO® - THE FIRST AND ONLY PSMA-targeted radioligand therapy for men with PSMA+ mCRPC who have been treated with androgen receptor pathway inhibitors and taxane-based chemotherapy.